Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9306566 | 0.90 | KMT2A (0.48) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL7864024 | 0.87 | MEN1 (0.44) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL21641668 | 0.85 | KMT2A (0.36) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL14677560 | 0.83 | TSHR (0.45) | KMT2AMEN1L3MBTL1CNR1ALDH1A1 | |
| SCHEMBL3630774 | 0.82 | ACP3 (0.53) | KMT2AMEN1L3MBTL1ALDH1A1TDP1 | |
| SCHEMBL4619006 | 0.81 | KMT2A (0.54) | KMT2AMEN1CACNA1CCNR1CNR2 | |
| SCHEMBL4619827 | 0.81 | MEN1 (0.45) | KMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL4776740 | 0.79 | SLC6A2 (0.47) | KMT2AMEN1L3MBTL1CNR1CNR2 | |
| SCHEMBL1551142 | 0.77 | CNR1 (0.56) | KMT2AMEN1L3MBTL1CNR1CNR2 | |
| SCHEMBL4273855 | 0.77 | MLKL (0.47) | KMT2AMEN1CACNA2D1CACNA1BCACNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256740-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256740-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256740-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155419-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155381-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155419-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155419-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2014-06-05 | — | — | US | disclosed |
| EP-2736332-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019653-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2013019653-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256740-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | KMT2A 1686/4885MEN1 4672/4885CACNA2D1 3189/4885 |
| US-20140155381-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | KMT2A 1686/4885MEN1 4672/4885CACNA2D1 3189/4885 |
| US-20140155419-A1 | COMPOUNDS AND METHODS | RORC, RORB, RORA | KMT2A 1686/4885MEN1 4672/4885CACNA2D1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.